臨床検査52巻5号

2008年05月発行

今月の主題 自己免疫疾患の診断 各論―抗体と疾患

抗CCP抗体の臨床的意義

著者： 北原加奈子¹² 川合眞一¹

所属機関： ¹東邦大学医療センター大森病院膠原病科 ²東邦大学免疫学講座

ページ範囲：P.511 - P.517

　関節リウマチは，関節滑膜の慢性炎症を主病変とする自己免疫疾患であり，進行すると関節破壊に至る．その診断はアメリカリウマチ協会の分類基準に基づいて行われるが，早期例ではこの基準を満たさないことも珍しくない．リウマトイド因子(RF)は分類基準に唯一含まれる血清学的マーカーであるが，関節リウマチ以外の疾患でも陽性となりうる．近年，特異性の高い自己抗体として抗CCP(環状シトルリン化ペプチド)抗体が注目されている．抗CCP抗体検査は，関節リウマチの早期診断に加え，その予後予測にも役立つ可能性が示唆される．

参考文献

１) Anderson R：Rheumatoid arthritis. In：Primer on the Rheumatic Diseases, Twelfth ed (Klippel J, Crofford L, Stone J, et al eds), the Arthritis Foundation, Atlanta, pp218-224, 2001

２) Arnett FC, Edworthy SM, Bloch DA, et al：The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum　31：315-324, 1988

３) Kawai S：Current drug therapy for rheumatoid arthritis. J Orthop Sci　8：259-263, 2003

４) Guidelines for the management of rheumatoid arthritis：2002 Update. Arthritis Rheum　46：328-346, 2002

５) 越智隆弘，山本一彦，龍順之助：診断のマニュアルとEBMに基づく治療ガイドライン，財団法人日本リウマチ財団，2004

６) Bridges S, Davidson A：Rheumatoid factor. In：Arthritis and Allied Conditions：A Textbook of Rheumatology, Fifteenth ed(Koopman W, Moreland L, eds), Lippincott Williams ＆ Wilkins, Philadelphia, pp1227-1247, 2005

７) Imafuku Y, Yoshida H, Yamada Y：Reactivity of agalactosyl IgG with rheumatoid factor. Clin Chim Acta　334：217-223, 2003

８) Nienhuis RL, Mandema E：A new serum factor in patients with rheumatoid arthritis；the antiperinuclear factor. Ann Rheum Dis　23：302-305, 1964

９) Young BJ, Mallya RK, Leslie RD, et al：Anti-keratin antibodies in rheumatoid arthritis. Br Med J　2：97-99, 1979

10) Sebbag M, Simon M, Vincent C, et al：The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest　95：2672-2679, 1995

11) Schellekens GA, de Jong BA, van den Hoogen FH, et al：Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest　101：273-281, 1998

12) Suzuki A, Yamada R, Chang X, et al：Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet　34：395-402, 2003

13) Iwamoto T, Ikari K, Nakamura T, et al：Association between PADI4 and rheumatoid arthritis：a meta-analysis. Rheumatology(Oxford)　45：804-807, 2006

14) Cantaert T, De Rycke L, Bongartz T, et al：Citrullinated proteins in rheumatoid arthritis：crucial... but not sufficient! Arthritis Rheum　54：3381-3389, 2006

15) van Gaalen FA, Visser H, Huizinga TW：A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides(CCP1 and CCP2)autoantibody tests for rheumatoid arthritis. Ann Rheum Dis　64：1510-1512, 2005

16) van Venrooij WJ, Zendman AJ, Pruijn GJ：Autoantibodies to citrullinated antigens in(early)rheumatoid arthritis. Autoimmun Rev　6：37-41, 2006

17) Avouac J, Gossec L, Dougados M：Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis：a systematic literature review. Ann Rheum Dis　65：845-851, 2006

18) Nishimura K, Sugiyama D, Kogata Y, et al：Meta-analysis：diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med　146：797-808, 2007

19) Bizzaro N, Tonutti E, Tozzoli R, et al：Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem　53：1527-1533, 2007

20) Kitahara K, Takagi K, Kusunoki Y, et al：Clinical value of second and third generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Ann Rheum Dis(in press)

21) Nell VP, Machold KP, Stamm TA, et al：Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis　64：1731-1736, 2005

22) Nielen MM, van der Horst AR, van Schaardenburg D, et al：Antibodies to citrullinated human fibrinogen(ACF)have diagnostic and prognostic value in early arthritis. Ann Rheum Dis　64：1199-1204, 2005

23) Raza K, Breese M, Nightingale P, et al：Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol　32：231-238, 2005

24) van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al：Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis：a prospective cohort study. Arthritis Rheum　50：709-715, 2004

25) Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al：Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum　48：2741-2749, 2003

26) Nielen MM, van Schaardenburg D, Reesink HW, et al：Specific autoantibodies precede the symptoms of rheumatoid arthritis：a study of serial measurements in blood donors. Arthritis Rheum　50：380-386, 2004

27) Berglin E, Padyukov L, Sundin U, et al：A combination of autoantibodies to cyclic citrullinated peptide(CCP)and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther　6：R303-R308, 2004

28) Berglin E, Johansson T, Sundin U, et al：Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis　65：453-458, 2006

29) Forslind K, Ahlmen M, Eberhardt K, et al：Prediction of radiological outcome in early rheumatoid arthritis in clinical practice：role of antibodies to citrullinated peptides(anti-CCP). Ann Rheum Dis　63：1090-1095, 2004

30) Lindqvist E, Eberhardt K, Bendtzen K, et al：Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis　64：196-201, 2005

31) Machold KP, Stamm TA, Nell VP, et al：Very recent onset rheumatoid arthritis：clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology(Oxford)　46：342-349, 2007

32) Meyer O, Labarre C, Dougados M, et al：Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis　62：120-126, 2003

33) Sanmarti R, Gomez-Centeno A, Ercilla G, et al：Prognostic factors of radiographic progression in early rheumatoid arthritis：a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol　26：1111-1118, 2007

34) Tamai M, Kawakami A, Uetani M, et al：The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis. Ann Rheum Dis　65：133-134, 2006

35) Vallbracht I, Rieber J, Oppermann M, et al：Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis　63：1079-1084, 2004

36) van Venrooij WJ, Hazes JM, Visser H：Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med　60：383-388, 2002

37) De Rycke L, Peene I, Hoffman IE, et al：Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis：diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis　63：1587-1593, 2004

38) Ronnelid J, Wick MC, Lampa J, et al：Longitudinal analysis of citrullinated protein/peptide antibodies(anti-CP)during 5 year follow up in early rheumatoid arthritis：anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis　64：1744-1749, 2005

39) Bobbio-Pallavicini F, Caporali R, Alpini C, et al：Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci　1109：287-295, 2007

40) Cambridge G, Leandro MJ, Edwards JC, et al：Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum　48：2146-2154, 2003

41) Toubi E, Kessel A, Slobodin G, et al：Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis　66：818-820, 2007

42) Combe B, Landewe R, Lukas C, et al：EULAR recommendations for the management of early arthritis：report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics(ESCISIT). Ann Rheum Dis　66：34-45, 2007